{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T04:00:39Z","timestamp":1762056039220,"version":"build-2065373602"},"reference-count":41,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer"},{"name":"EOL-Labs Scientific Consultancy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: The increasing prevalence of multidrug-resistant Enterobacteriaceae limits the range of active antimicrobial agents, thus worsening clinical outcomes. The objective of this study was to identify the trends in antimicrobial resistance for Enterobacteriaceae in Russia using the databases for the International Network for Optimal Resistance Monitoring (INFORM) and Antimicrobial Testing Leadership and Surveillance (ATLAS) studies between 2012 and 2018. Methods: This subanalysis was performed for 3811 non-duplicate clinical isolates of Enterobacteriaceae to evaluate the in vitro activity of the main classes of antibiotics against relevant clinical isolates from hospitalized patients with complicated infections of different anatomical locations. Results: The lowest susceptibility was observed for colistin (0%), ampicillin (16.4%), and ampicillin\/sulbactam (31.1%), whereas the best susceptibility was observed for all combinations containing avibactam (&gt;96%). Among individual antimicrobials, doripenem (3.2%), tigecycline (1.6%), and meropenem (5.9%) exhibited the lowest resistance. Important trends included the decreasing resistance of Enterobacteriaceae to glycylcyclines and the increasing resistance to aminoglycosides and carbapenems. K. pneumoniae strains were most aggressive in terms of the percentage of strains having multidrug resistance (8.3\u201318.3%, depending on location) and the percentage of ESBL-positive strains (44.8\u201386.8%). Conclusions: The current patterns and trends of antimicrobial resistance in different bacterial species should be taken into consideration for timely updating of clinical guidelines and local treatment protocols to ensure effective antimicrobial therapy.<\/jats:p>","DOI":"10.3390\/antibiotics11060790","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T10:25:12Z","timestamp":1654856712000},"page":"790","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Dynamics of Antimicrobial Resistance among Enterobacteriaceae Isolates in Russia: Results of the 2012\u20132018 INFORM and ATLAS International Program Studies"],"prefix":"10.3390","volume":"11","author":[{"given":"Roman","family":"Kozlov","sequence":"first","affiliation":[{"name":"Smolensk State Medical Academy, 214019 Smolensk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Kuzmenkov","sequence":"additional","affiliation":[{"name":"Smolensk State Medical Academy, 214019 Smolensk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13756-018-0346-9","article-title":"A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States","volume":"7","author":"Livorsi","year":"2018","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/1560-7917.ES.2017.22.31.30583","article-title":"Evolving beta-lactamase epidemiology in Enterobacteriaceae from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among outpatients","volume":"22","author":"Giani","year":"2017","journal-title":"Eurosurveillance"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/jac\/dkz456","article-title":"In vitro activity of ceftazidime\/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015\u20132017)","volume":"75","author":"Spiliopoulou","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2015.09.015","article-title":"National epidemiology of carbapenem-resistant and extensively drug-resistant Gram-negative bacteria isolated from blood samples in China in 2013","volume":"22","author":"Xu","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e2016032","DOI":"10.4084\/mjhid.2016.032","article-title":"Epidemiology of Carbapenem Resistant Klebsiella pneumoniae Infections in Mediterranean Countries","volume":"8","author":"Corrado","year":"2016","journal-title":"J. Hematol. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/jac\/dky027","article-title":"Treatment of infections caused by multidrug-resistant gram-negative bacteria: Report of the British society for antimicrobial chemotherapy\/healthcare infection society\/british infection association joint working party","volume":"73","author":"Hawkey","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","article-title":"The epidemiology of Carbapenem-resistant enterobacteriaceae: The impact and evolution of a global menace","volume":"215","author":"Logan","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e00310-16","DOI":"10.1128\/mSphere.00310-16","article-title":"Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial","volume":"2","author":"Giammanco","year":"2017","journal-title":"mSphere"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1473-3099(17)30394-8","article-title":"Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998\u20132016): A surveillance study","volume":"17","author":"Musicha","year":"2017","journal-title":"Lancet Infect. Dis."},{"doi-asserted-by":"crossref","unstructured":"Wang, S., Zhao, S.Y., Xiao, S.Z., Gu, F.F., Liu, Q.Z., Tang, J., Guo, X.K., Ni, Y.X., and Han, L.Z. (2016). Antimicrobial resistance and molecular epidemiology of Escherichia coli causing bloodstream infections in three hospitals in Shanghai, China. PLoS ONE, 11.","key":"ref_10","DOI":"10.1371\/journal.pone.0147740"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/jms.jms_25_17","article-title":"World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","volume":"32","author":"Shrivastava","year":"2018","journal-title":"JMS J. Med. Soc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.2147\/IDR.S226649","article-title":"In vitro activity of ceftaroline and comparators against staphylococcus aureus isolates: Results from 6 years of the ATLAS program (2012 to 2017)","volume":"12","author":"Zhang","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1429.e1","DOI":"10.1016\/j.cmi.2019.03.023","article-title":"Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections","volume":"25","author":"Stone","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1128\/AAC.02841-15","article-title":"Assessment of the in vitro activity of ceftazidime-avibactam against multidrug-resistant Klebsiella spp. collected in the INFORM Global Surveillance Study, 2012 to 2014","volume":"60","author":"Hackel","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/ofid\/ofy347","article-title":"Variations in the occurrence of resistance phenotypes and carbapenemase genes among enterobacteriaceae isolates in 20 years of the SENTRY antimicrobial surveillance program","volume":"6","author":"Castanheira","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"115505","DOI":"10.1016\/j.diagmicrobio.2021.115505","article-title":"Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia","volume":"101","author":"Hovan","year":"2021","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14757","DOI":"10.1038\/s41598-021-94295-1","article-title":"Epidemiology, risk factors, and prediction score of carbapenem resistance among inpatients colonized or infected with 3rd generation cephalosporin resistant Enterobacterales","volume":"11","author":"Moghnieh","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e00592-18","DOI":"10.1128\/AAC.00592-18","article-title":"In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program from 2012 to 2015","volume":"62","author":"Kazmierczak","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijantimicag.2018.07.003","article-title":"In vitro activity of tigecycline and comparators (2014\u20132016) among key WHO \u2018priority pathogens\u2019 and longitudinal assessment (2004\u20132016) of antimicrobial resistance: A report from the T.E.S.T. study","volume":"52","author":"Seifert","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijantimicag.2016.01.008","article-title":"Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010\u20132013","volume":"47","author":"Jean","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11875","DOI":"10.1038\/s41598-021-90382-5","article-title":"Molecular characterization of multidrug resistant Enterobacterales strains isolated from liver and kidney transplant recipients in Spain","volume":"11","author":"Marco","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"115512","DOI":"10.1016\/j.diagmicrobio.2021.115512","article-title":"Trends of major antimicrobial resistance phenotypes in enterobacterales and gram-negative non-fermenters from ATLAS and EARS-net surveillance systems: Italian vs. European and global data, 2008-2018","volume":"101","author":"Rossolini","year":"2021","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13756-021-00994-9","article-title":"Admission screening and cohort care decrease carbapenem resistant enterobacteriaceae in Vietnamese pediatric ICU\u2019s","volume":"10","author":"Garpvall","year":"2021","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Molecular and Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae in the United States: A Prospective Cohort Study","volume":"20","author":"Arias","year":"2020","journal-title":"Lancet Infect Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.36488\/cmac.2019.2.147-159","article-title":"Antimicrobial resistance of nosocomial Enterobacterales isolates in Russia: Results of multicenter epidemiological study \u201cMARATHON 2015\u20132016\u201d","volume":"21","author":"Sukhorukova","year":"2019","journal-title":"Clin. Microbiol. Antimicrob. Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/jac\/dky266","article-title":"In vitro activity of ceftazidime\/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012\u20132015","volume":"73","author":"Kazmierczak","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13756-018-0360-y","article-title":"The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016","volume":"7","author":"Decousser","year":"2018","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S1473-3099(18)30353-0","article-title":"Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998\u20132016: A study of electronic health records","volume":"18","author":"Vihta","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/cid\/ciz1155","article-title":"Monitoring ceftazidime-avibactam and aztreonam concentrations in the treatment of a bloodstream infection caused by a multidrug- resistant enterobacter sp. carrying both klebsiella pneumoniae carbapenemase-4 and new delhi metallo-\u03b2-lactamase-1","volume":"71","author":"Yasmin","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13756-021-00938-3","article-title":"Colonization with multidrug-resistant Enterobacteriaceae among infants: An observational study in southern Sri Lanka","volume":"10","author":"Meredith","year":"2021","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13756-021-00950-7","article-title":"Molecular epidemiology of carbapenem-resistant Enterobacterales in Thailand, 2016\u20132018","volume":"10","author":"Paveenkittiporn","year":"2021","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL-producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01814-18","article-title":"In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM global surveillance program, 2012 to 2015","volume":"63","author":"Karlowsky","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e01820-16","DOI":"10.1128\/AAC.01820-16","article-title":"In Vitro Activity of Ceftazidime- Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime- Nonsusceptible Gram-Negative Pathogens","volume":"61","author":"Stone","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1093\/jac\/dkaa278","article-title":"Susceptibility trends of ceftolozane\/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18","volume":"75","author":"Sader","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jiac.2018.01.003","article-title":"Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016","volume":"24","author":"Tsutsui","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1517\/14656566.2016.1145658","article-title":"Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: Can we apply \u201cprecision medicine\u201d to antimicrobial chemotherapy?","volume":"17","author":"Perez","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1086\/592412","article-title":"Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies","volume":"29","author":"Patel","year":"2008","journal-title":"Infect. Control Hosp. Epidemiol."},{"unstructured":"(2018). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 11th ed (Standard No. CLSI Standard M07).","key":"ref_39"},{"unstructured":"EUCAST (2022, June 08). The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 10.0. Available online: http:\/\/www.eucast.org.","key":"ref_40"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013","volume":"59","author":"Lob","year":"2015","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/6\/790\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:27:35Z","timestamp":1760138855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/6\/790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["antibiotics11060790"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11060790","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2022,6,10]]}}}